Holen Sie sich die Stockscreener-App
3.015
0.50%
0.015
Handel nachbörslich:
3.02
0.005
+0.17%
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
Jefferies reiterates AC Immune stock Buy rating on vaccine data - Investing.com India
AC Immune 2025 Financials: Annual Loss of $85M, Q4 Revenue $423KNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
AC Immune Posts 2025 Results, Sharpens Pipeline Focus and Extends Cash Runway to 2027 - TipRanks
ACIU: Positive interim results for ACI-7104 and strategic focus extend cash runway to Q3 2027 - TradingView
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year - TipRanks
AC Immune: Fourth Quarter Financial Results Overview - Bitget
AC Immune: Q4 Earnings Snapshot - marketscreener.com
ACIU: Net loss increased to CHF 70.4 million in 2025 as revenue declined and R&D costs remained high - TradingView
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewswire
AC Immune SA expected to post a loss of 17 rappen a shareEarnings Preview - TradingView
Risk Report: What is AC Immune SAs book value per shareJuly 2025 Pullbacks & Intraday High Probability Alerts - baoquankhu1.vn
Aug Big Picture: Should I buy AC Immune SA stock nowJuly 2025 Patterns & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Hedge Fund Bets: What is the long term forecast for AC Immune SA stockJuly 2025 Closing Moves & Daily Oversold Bounce Ideas - baoquankhu1.vn
AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 - GlobeNewswire
AC Immune (NASDAQ:ACIU) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Will AC Immune SA stock hit new highs in YEAR2025 Historical Comparison & Risk Controlled Swing Alerts - baoquankhu1.vn
AC Immune (ACIU) Begins Phase 1 Trial for New Inflammation Treat - GuruFocus
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor - Investing.com Nigeria
AC Immune Doses First Participant in Phase 1 Trial of NLRP3 Inhibitor ACI-19764 - TipRanks
AC Immune begins phase 1 trial of brain-penetrant NLRP3 inhibitor By Investing.com - Investing.com South Africa
AC Immune (NASDAQ: ACIU) begins Phase 1 test of NLRP3 inhibitor ACI-19764 - Stock Titan
AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor - The Manila Times
Can AC Immune SA deliver consistent EPS growthMarket Volume Report & Community Verified Trade Signals - mfd.ru
ACIU Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug EndMonth: Can AC Immune SA deliver consistent EPS growthTrade Volume Report & Entry and Exit Point Strategies - baoquankhu1.vn
J&J Pauses Enrollment In Trial Of AC Immune-Partnered Anti-Tau Immunotherapy - Citeline News & Insights
AC Immune Says Recruitment Temporarily Paused in Ongoing Study for Alzheimer's Disease Treatment - marketscreener.com
Is AC Immune SA stock a buy before product launchesMarket Growth Review & Advanced Swing Trade Entry Alerts - mfd.ru
AC Immune (ACIU) Faces Enrollment Pause in Alzheimer's Trial wit - GuruFocus
AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027 - TipRanks
AC Immune SA announces voluntary suspension of recruitment for its Phase II clinical trial (code-named Retain) for Alzheimer's disease treatment - Bitget
AC Immune (NASDAQ: ACIU) details Alzheimer’s trial pause and 2027 cash runway - Stock Titan
Sagimet Biosciences (NASDAQ:SGMT) vs. AC Immune (NASDAQ:ACIU) Financial Survey - Defense World
Should I buy AC Immune SA stock nowWeekly Loss Report & Verified Trade Idea Suggestions - mfd.ru
What is AC Immune SA s debt to equity ratioEarnings Trend Report & Risk Controlled Swing Alerts - mfd.ru
What is AC Immune SA’s book value per shareWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - mfd.ru
Aug Movers: Can AC Immune SA weather a recessionJuly 2025 Institutional & Weekly Top Gainers Trade List - baoquankhu1.vn
Is AC Immune SA undervalued by DCF analysisJuly 2025 Recap & AI Driven Stock Price Forecasts - mfd.ru
What is AC Immune SA s revenue forecastJuly 2025 Decliners & Target Return Focused Stock Picks - mfd.ru
Bank Watch: Does AC Immune SA outperform in volatile marketsMarket Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Earnings Beat: Should I trade or invest in CVLGJuly 2025 Market Mood & Low Volatility Stock Suggestions - baoquankhu1.vn
Aug Analyst Calls: Can AC Immune SA weather a recession2025 Market Sentiment & Target Return Focused Stock Picks - baoquankhu1.vn
AC Immune (NASDAQ:ACIU) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Can AC Immune SA weather a recession2025 Valuation Update & Weekly Watchlist for Consistent Profits - mfd.ru
Does AC Immune SA outperform in volatile markets2025 Valuation Update & Weekly High Conviction Ideas - mfd.ru
Will AC Immune SA outperform its industry peersQuarterly Trade Review & Reliable Breakout Stock Forecasts - mfd.ru
Performance Recap: Is Stagwell Inc stock forming a cup and handleGDP Growth & Low Risk High Win Rate Picks - baoquankhu1.vn
Dip Buying: Should I buy AC Immune SA stock nowJuly 2025 Opening Moves & Fast Gain Swing Alerts - baoquankhu1.vn
Will AC Immune SA outperform the market in YEAR2025 Key Highlights & High Win Rate Trade Alerts - Mfd.ru
AC Immune (NASDAQ:ACIU) Stock Price Down 5.4%Time to Sell? - MarketBeat
Profit Recap: Will AC Immune SA outperform its industry peersIPO Watch & Growth Focused Stock Reports - baoquankhu1.vn
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):